New perspectives with targeted drugs

Fabio Barra, Giulio Evangelisti, Giuseppe Damiano, Serafina Mammoliti, Simone Ferrero

Research output: Chapter in Book/Report/Conference proceedingChapter


Endometrial cancer (EC) is the most frequent malignancy of the female reproductive tract in Western countries. Although the majority of patients have an early stage disease that has a good prognosis after the curative surgical treatment, a significant number of metastatic or recurrent disease are still diagnosed. For those patients not amenable to surgical treatments, only alternative therapies, such as radiotherapy or chemotherapy, remains the standard of care. Anyway, outcome of these women is poor, thus, new treatment options are demanding. From last years, the genetic alterations responsible for development, growth and progression of EC are being elucidated, reclassifying this disease in distinct subtypes with different mechanisms of physiopathology. This has paved the way to the investigation of novel drugs that with specific molecular targeted mechanisms. This approach perspective for a tailored treatment and an improvement of response and survival rates for heavily treated recurrent disease.

Original languageEnglish
Title of host publicationEndometrial Cancer
Subtitle of host publicationRisk Factors, Management and Prognosis
PublisherNova Science Publishers, Inc.
Number of pages14
ISBN (Electronic)9781536138887
ISBN (Print)9781536138870
Publication statusPublished - Jan 1 2018



  • EGFR
  • Endometrial cancer
  • mTor inhibitors
  • PARP inhibitors
  • Targeted therapy
  • VEGF

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Barra, F., Evangelisti, G., Damiano, G., Mammoliti, S., & Ferrero, S. (2018). New perspectives with targeted drugs. In Endometrial Cancer: Risk Factors, Management and Prognosis (pp. 301-314). Nova Science Publishers, Inc..